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Potential role of zinc in the visceromegaly regression and 
recovery of hematological parameters during treatment of 
visceral leishmaniasis in children from an endemic area
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ABSTRACT
Leishmaniasis is a disease complex with various clinical symptoms caused by different 
species of parasites of the genus Leishmania. The visceral form of the disease, characterized 
by severe symptoms is fatal, if not treated. The high toxicity of current antileishmanial drugs 
and the need for long-term treatment make the therapy complicated, especially in a large 
number of infected children. Hence, the search for new therapies must be intensified. Oral 
administration of the trace element zinc has been considered in alternative treatments against 
different clinical forms of leishmaniasis. This study revealed that the administration of zinc 
in children with visceral leishmaniasis, during treatment with amphotericin B or glucantime, 
accelerates the regression of the spleen enlargement without interfering with the recovery 
of hematological parameters. 
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INTRODUCTION
Visceral leishmaniasis (VL) is a zoonotic infectious disease which is caused in 
Americas by the protozoan parasite Leishmania infantum (L. infantum) transmitted 
through the bite of female infected phlebotomine sand flies Lutzomyia longipalpis 
(L. longipalpis)1. According to the World Health Organization (WHO), VL causes 
more than 20,000 deaths each year worldwide2. Among symptomatic patients, the 
main clinical signals of VL include intermittent fever, weight loss, adenopathy, 
anemia and substantial enlargement of the spleen and liver. In advanced stages 
of the disease, a consequence of the increase in the spleen and liver is intense 
abdominal distention and pain3. If patients are left untreated, the mortality rate can 
reach 100% within 2 years4. 
Despite the high toxicity, the need for intravenous administration and the need 
for hospitalization and monitoring during treatment, the antileishmanial drugs 
amphotericin B and glucantime are used as first-line drugs in several countries5,6. 
Nowadays, many studies are conducted to determine alternative drugs to treat 
neglected diseases with lower toxicity and costs and to identify methods to increase 
the efficacy of current drugs, decreasing the side effects7,8. The efficacy of the trace 
element zinc (Zn) has been tested in a murine model of infection by L. major9 
and in human cases of cutaneous leishmaniasis10. Since Zn plays an essential 
role in improving the nutritional and immunological status11, considered crucial 
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parameters for the clinical progression of patients with VL 
in response to treatment, in this study we evaluated the 
role of zinc supplementation, combined with conventional 
antileishmanial therapy, in the regression of hepatomegaly 
and splenomegaly and recovery of hematological 
parameters in children with VL.
PATIENTS AND METHODS
Patients and Ethics Statement
Fifty-two patients with VL and fifteen healthy children 
aged 9–144 months were recruited to this study from 
the Hospital Maria Aparecida Pedrossian – HUMAP, 
Universidade Federal do Mato Grosso do Sul, Campo 
Grande, MS, Brazil. VL was suspected in patients with 
fever and splenomegaly. Diagnosis was confirmed through 
detection of amastigote forms of the parasite in bone marrow 
aspiration samples. The healthy children included in this 
study were recruited during pediatric queries for routine 
examination. Patients with other diseases were excluded. 
Prior to the recruitment of patients, the study was approved 
by the Research Ethics Committee of the University (Protocol 
Nº 2207/0305.0.049.000-11). Written informed consents 
were obtained from parents or legal guardians of the minors.
Treatment and zinc supplementation
All patients were treated with amphotericin B 
(0.5–1 mg/kg/day administered intravenously) or meglumine 
antimoniate (glucantime®) (20 mg/kg/day administered 
intravenously) for 20 days. During treatment, patients were 
divided into two groups: one group received conventional 
treatment alone, while the other group received both 
conventional treatment and a syrup containing zinc in the 
form of a chelate solution (10 mg/ml). The group received 
a total dose of 2 mg/kg/day in 14 days. 
Plasma zinc analysis
On days 1, 7 and 14 of treatment, blood samples were 
collected in polypropylene syringes and immediately 
transferred to vacuum tubes free of trace elements (BD 
Vacutainer Systems). Plasma samples were separated by 
centrifugation and stored at -20 °C for analytical analysis. 
All plastic or glass materials were previously treated for 
decontamination. The calibration curves were constructed 
using four different zinc concentrations with values ranging 
from 0.25-2.0 mg/L. Atomic absorption analyses for 
plasma zinc were performed using a Perkin Elmer AA100 
spectrometer (Waltham, MA, USA). 
Liver and spleen measurement
On days 1, 7 and 14 of treatment, liver and the spleen 
enlargement were measured using percussion methods and 
a flexible measuring tape. Measurements for all patients 
were performed by the same researcher during the entire 
study period. The liver was measured at the level of the 
right hemiclavicular line, and the spleen was measured at 
the level of the transverse line drawn perpendicular to the 
left costal margin. The longitudinal and transversal lengths 
of the spleen were used to calculate the area of the organ 
using the formula of an elliptic area.
Classification of the nutritional status
The nutritional status was classified based on the World 
Health Organization (WHO) weight-for-age growth charts12 
used for monitoring the growth of children. 
Serum albumin quantification
On days 1, 7 and 14 after the beginning of treatment, 
blood samples were collected in collection tubes 
(BD microtainer®), serum samples were separated by 
centrifugation and the albumin levels were measured using a 
specific kit (ALB2 Roche®) according to the manufacturer’s 
instructions.
Total blood count
On days 1, 7 and 14 after the beginning of treatment, 
blood samples were collected intravenously from all 
patients using specific blood collection tubes (BD 
microtainer®). Hematologic parameters were assessed in a 
Sysmex XN3000™ hematology analyzer. 
Statistical analysis
Data were expressed as means ± SEM. The statistical 
significances between different time points were calculated 
using the Student’s t test. All analyses were performed 
using the PRISM 5.0 software. Results were considered 
statistically different when the p value was < 0.05.
RESULTS AND DISCUSSION
Before the beginning of treatment, plasma Zn levels in 
all patients was measured (Figure 1A). Some studies showed 
that plasma Zn levels in patients with VL were lower than 
those of healthy individuals13,14. Our results have shown that 
plasma Zn levels were lower in patients supplemented with 
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Zn than in patients who did not receive Zn supplementation, 
despite this, none of the groups presented plasmatic Zn 
levels lower than healthy children (Figure 1A). Even when 
Zn levels are within the normal range, patients can receive 
the mineral supplementation as a preventive measure15. 
Moreover, less than 0.2% of the total body Zn content 
circulates are present in plasma samples16; hence, it may not 
be a reliable indicator to assess the Zn levels in tissues. The 
supplementation of Zn was performed in a blind manner, 
and the quantification of the trace element on days 1, 7 
and 14 after the beginning of supplementation showed that 
plasma Zn levels gradually increased (Figure 1B), while 
it remained unchanged in patients who did not receive Zn 
supplementation (Figure 1C).
The mean age and gender were not significantly different 
between children who received Zn supplementation and 
those who did not receive Zn supplementation during 
treatment of VL (Table 1). Previous studies showed that 
Figure 1 - A) Initial plasma zinc levels quantificated in healthy children (n=15) and in patients with visceral leishmaniasis before 
the beginning of zinc supplementation (n=23) or in those who did not receive zinc supplementation (n=29); B) Plasmatic zinc levels 
quantificated on days 1, 7, and 14 of zinc supplementation and treatment with amphotericin B or glucantime in patients with visceral 
leishmaniasis (n=23); C) Plasmatic zinc levels quantificated on days 1, 7, and 14 of treatment with amphotericin B or glucantime in 
patients with visceral leishmaniasis who did not receive zinc supplementation (n=29); D) Serum albumin levels of healthy children 
and patients with visceral leishmaniasis with and without zinc supplementation on days 1, 7, and 14 of treatment with amphotericin 
B or glucantime. The reference interval was delimited by dashed lines according to the values proposed by the kit manufacturer. 
*p< 0.05 in A, B and D, #p< 0.05 compared with healthy controls in D and ns=not statistically different in A–C 
Carbone et al.
Rev Inst Med Trop São Paulo. 2018;60:e50Page 4 of 7
VL in Brazil has a great incidence in children17,18. Although 
literature suggests predominance of the disease in male 
gender19, our data are in accordance with the results of 
Queiroz et al.’s study20, who found the same distribution of 
the disease between children of both genders. An important 
risk factor of severe VL is malnutrition21. In this study, most 
of the recruited patients had normal nutritional status based 
on the weight-for-age indicator in the WHO growth charts 
(Table 1). Although serum albumin levels were used to 
evaluate the nutritional status, albumin levels are not specific 
to detect malnutrition and can be affected by some factors, 
such as inflammation22. Similarly to the results obtained 
by Gatto et al.23, here we showed that serum albumin is 
slightly reduced during VL and the treatment of children, 
whether using amphotericin B or glucantime alone or in 
combination with Zn supplementation, increases serum 
albumin to normal levels (Figure 1D).
The earliest signs of improvement in the condition of 
patients with VL are the regression of clinical symptoms 
and splenomegaly. This study revealed that patients 
who received Zn supplementation during treatment with 
amphotericin B or glucantime showed rapid reduction in 
the spleen size compared with those patients who did not 
receive Zn (Figure 2A). On day 7 of treatment, patients 
supplemented with Zn had a significant reduction in the 
area of spleen, while patients without Zn supplementation 
presented considerable regression of splenomegaly only 
20 days after the beginning of treatment (Figure 2A). The 
reduction of hepatomegaly was also evaluated in patients. 
On day 7 of treatment, patients supplemented with Zn 
presented a slight reduction in the liver size (Figure 2B); 
however, a significant reduction occurred in both groups 
of patients on day 14 of treatment (Figure 2B). In our 
model, we found that Zn supplementation only accelerates 
the splenomegaly regression but not the hepatomegaly in 
patients with VL. However, we believe that these data are 
still interesting as most studies showed that splenomegaly 
is more commonly observed than hepatomegaly among 
patients with VL. Enlargement of spleen is reported in about 
90% of patients24, while the liver involvement is observed 
in less than 30% of patients25. 
During the treatment of VL, recovery of hematological 
parameters were among the signs that indicated an 
improvement in patients’ conditions26; hence, in this study, 
leukocytes and hemoglobin levels were evaluated in blood 
samples of patients. Treatment with amphotericin B or 
glucantime increased leukocyte and hemoglobin levels in both 
groups (Figures 2C and 2D). Moreover, Zn supplementation 
did not interfere with hematological parameters of patients 
during treatment of VL (Figures 2C and 2D). Our data are not 
in agreement with those of Dunchateau et al.27, who showed 
that Zn supplementation increased the circulating number 
of T lymphocytes in elderly people. This disagreement can 
be explained by the high concentration of Zn administrated 
by Dunchateau et al.27 (400 mg/day) and because elderly 
patients were used in that study. On contrary, the results of 
our study are in accordance with those of Bonham et al.28 
who found that supplementation with 30 mg/kg/day of Zn 
in adult healthy men had no effect on the circulating levels 
of peripheral blood leukocytes subsets. 
Previous and recent studies have shown that, although 
both antileishmanial drugs are effective, children treated 
with amphotericin B showed faster clinical improvement 
and shorter hospital stay than those children treated 
with glucantime29,30. The main advantage of glucantime 
compared with amphotericin B is the lower cost, for 
this reason most patients in our study were treated with 
glucantime. Only a few patients received amphotericin B 
treatment, thus, we could not evaluate whether the choice of 
drug interfered with the results. Future studies are necessary 
to evaluate whether Zn supplementation has different results 
when used with amphotericin B or with glucantime alone.
Our data corroborate the importance of zinc 
supplementation favoring the regression of splenomegaly 
Table 1 - Age, gender and nutritional status of patients with VL and healthy children enrolled in the study
With Zn Without Zn Healthy 
Mean age (months) 46.20 ± 9.66 43.76 ± 6.50 44.60 ± 10.20
Male n=11 n=11 n=06
Female n=12 n=18 n=09
Nutritional status Number/Total (%)
Overweight 1/23 (4.35) 1/29 (3.45) 0
Overweight risk 2/23 (8.69) 3/29 (10.34) 0
Normal nutrition 18/23 (78.26) 24/29 (82.76) 15/15 (100)
Nutritional risk 1/23 (4.35) 1/29 (3.45) 0
Malnutrition 1/23 (4.35) 0 0
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in children during treatment of VL. These findings open 
new perspectives to increase the effectiveness of the current 
treatment of VL.
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